Search company, investor...

LuMend

lumend.com

Founded Year

1996

Stage

Acquired | Acquired

Total Raised

$46.87M

About LuMend

LuMend, Inc. is developing, manufacturing and marketing medical devices that meet clinical needs in interventional cardiology and radiology. The company's products are designed to cross chronic total occlusions (CTOs) and allow for subsequent treatment using catheter-based, minimally invasive procedures. Per the company, despite the high incidence of CTOs in patients with coronary and peripheral vascular disease, the catheter-based technology options available to treat these patients in a predictable, safe, reliable, and cost-effective manner are limited.

Headquarters Location

400 Chesapeake Drive

Redwood City, California, 94063,

United States

650-364-1400

Missing: LuMend's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: LuMend's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

LuMend Patents

LuMend has filed 2 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

4/26/2013

Medical equipment, Calcium channel blockers, Vascular diseases, Catheters, Hematology

Application

Application Date

4/26/2013

Grant Date

Title

Related Topics

Medical equipment, Calcium channel blockers, Vascular diseases, Catheters, Hematology

Status

Application

Latest LuMend News

Catheters Global Market Report 2022

Jun 7, 2022

" - https://www.reportlinker.com/p06284277/?utm_source=GNW Braun Melsungen AG, Terumo Corporation, Lumend Corporation, Covidien Ag (Ireland), Acist Medical Systems, Cook Medical Inc., Dickinson and Company, Stryker Corporation, and Merit Medical Systems. The global catheters market is expected to grow from $24.9 billion in 2021 to $27.32 billion in 2022 at a compound annual growth rate (CAGR) of 9.7%. The market is expected to grow to $34.92 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The catheter market consists of sales of catheters by entities (organizations, sole traders, and partnerships) that refers to a tubular device for insertion into vessels, canals, passageways, body cavities.Catheters are usually used to permit injection or withdrawal of fluids or to keep a passage open. The catheters are used for different medical purposes such as administration of fluids, medications or gases, or to drain fluids or urine from the body. The main types of catheters include cardiovascular, neurovascular, urology, intravenous, and specialty catheters.The cardiovascular catheters market consists of sales of catheters by entities (organizations, sole traders, and partnerships) that refer to the catheters that are used for cardiac purposes. Catheters are available in three variations single-lumen, double-lumen, and triple-lumen and used in hospitals and clinics and ambulatory surgical centers. North America was the largest region in the catheters market in 2021.Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the catheters market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The rising prevalence of the cardiovascular disorder is driving the growth of the catheters market.Cardiac catheterization is a process in which a catheter is moved through a blood vessel to the heart for a better diagnosis of health conditions. The increase in the prevalence of cardiovascular diseases and the growing demand for cardiovascular treatment is expected to increase the demand for catheters.For instance, the prevalence of cardiovascular diseases doubled from 271 million in 1990 to 523 million in 2019, and the key reasons for the rising prevalence of cardiovascular disorders are an increase in life spans, socio-economic changes, acquisition of lifestyle-related risk factors, and others. Thus, the rising prevalence of the cardiovascular disorder is expected to boost the catheters market. Strategic collaborations between companies are a key trend that is gaining popularity in the catheters market.Companies in the catheters market are focusing on strategic collaborations to expand their research and development activities in innovative products and improve their market share in their respective markets. For instance, in 2019, Stereotaxis and Osypka have collaborated on the development of a next-generation magnetic ablation catheter with the integration of robotic technology of Stereotaxis. This has stimulated the growth potential of both companies in the industry. In August 2019, Boston Scientific Corporation, a USA-based developer, manufacturer, and marketer of medical devices has acquired the British Technology Group (BTG plc.) for $4.2 billion. The acquisition by the company is focused on expanding its portfolio of minimally-invasive surgical devices and expanding its business presence in medical device markets. BTG is a UK-based medical device company involved in the development and commercialization of its products that are used in minimally-invasive procedures targeting cancer and vascular diseases. The countries covered in the catheters market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

LuMend Frequently Asked Questions (FAQ)

  • When was LuMend founded?

    LuMend was founded in 1996.

  • Where is LuMend's headquarters?

    LuMend's headquarters is located at 400 Chesapeake Drive, Redwood City.

  • What is LuMend's latest funding round?

    LuMend's latest funding round is Acquired.

  • How much did LuMend raise?

    LuMend raised a total of $46.87M.

  • Who are the investors of LuMend?

    Investors of LuMend include Cordis, Morgenthaler Ventures, De Novo Ventures, ABS Ventures, Palo Alto Investors and 7 more.

  • Who are LuMend's competitors?

    Competitors of LuMend include NeoChord, Reva Medical, Broncus Medical, Simbionix, Neuro Kinetics, Mitralign, Entellus Medical, Vexim, NeoGraft Technologies, Sequent Medical and 40 more.

Compare LuMend to Competitors

R
Reva Medical

REVA Medical develops interventional medical devices that leverage the company's stent designs and biomaterials to improve the treatment of vascular disease. Its flagship product is called MOTIV, a bioresorbable coronary stent that is designed to fulfill the temporary need for a stent and then fade away, leaving only the healed vessel behind. This product is utilized for the treatment of coronary artery disease. REVA Medical has a broad strategic relationship with Boston Scientific Corporation, a worldwide developer and marketer of interventional medical devices. The company was founded in 1998 and is based in San Diego, California.

X
XTENT

Based in Menlo Park, California, Xtent Inc. is a privately held developer of next generation drugeluting stent (DES) systems designed for the treatment of real-world patients, including those with complex, multi-lesion or multi-vessel coronary and peripheral vascular disease. Although the drugeluting stent (DES) market is today dominated by large companies, the interventional cardiology field has seen many technological breakthroughs that have changed market leadership.

NeoChord Logo
NeoChord

NeoChord is a medical technology company engaged in the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company's flagship product, the NeoChord Artificial Chordae Delivery System, is a beating heart procedure, echo-guided treatment for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. The company was founded in 2007 and is based in Minneapolis, Minnesota.

C
CryoPen

CryoPen is a developer and manufacturer of state-of-the art medical devices and aesthetic treatment systems. CryoPen is committed to delivering the most effective, and profitable solutions available to healthcare providers, physicians of all specialties, and medical spas. The company's product portfolio aims to enable physicians to provide a higher quality of care and offer their patients a more diverse array of treatments while generating a substantial revenue stream for their practice. CryoPen's product set addresses a multitude of treatment applications such as laser hair removal, skin rejuvenation, cryosurgery, cellulite reduction, vascular lesions, pigmented lesions, acne, psoriasis, fine lines & wrinkles, scar and tattoo removal, photo facials, and skin tightening. With a dedication to the research and development of technologically advanced devices and equipment, every CryoPen product is designed to create a better patient experience, consistent clinical outcomes, and economic impact on the bottom line of their practice.

D
Disc Dynamics

Disc Dynamics has developed the DASCORTM Disc Arthroplasty System, an innovative, minimally invasive nucleus replacement treatment for patients suffering from chronic low back pain caused by Degenerative Disc Disease (DDD).

Endologix Logo
Endologix

Endologix is a developer and manufacturer of minimally invasive treatments for vascular diseases. Endologix is focusing on the development and marketing of its patented technology for the treatment of Abdominal Aortic Aneurysms (AAA). An aneurysm is a weakening of the wall of the aorta, the largest artery of the body. Aortic aneurysm disease is a cause of death in the United States and it is estimated that 1.7 million persons over 55 years of age have an AAA. Each year, physicians diagnose approximately 200,000 people in the United States with AAA. Endologix is currently marketing its Powerlink Delivery System a, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. Powerlink has been commercially available in Europe since 1999. FDA approval for the Powerlink AAA stent graft was received on October 29, 2004. The Powerlink superior design is covered by 17 U.S. patents with 361 allowed claims; the technology is designed to overcome shortcomings of first-generation ELGs. The device is for sale in the United States and selected international markets. Endologix is a publicly-held company trading on NASDAQ: ELGX. The company's corporate office is located in Irvine, California.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.